Tag Archives: Genentech

Hepatitis C: Engaging Patients Online

By Ben Comer | Published: November 16, 2012
Given the amount of activity in the hepatitis C drug development space – as evidenced in PharmExec’s 2013 Pipeline report – patients are scouring the internet for information on the disease, available treatments, and soon to be available treatments. A new Industry Standard Research report examines the digital cracks consumers encounter when looking for [...]
Posted in Advertising, E-Media, Marketing, Strategy, multimedia, patient education, social media | Also tagged , , , , , , | Leave a comment

New Non-Profit Alliance of Big Pharma Firms

By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
Posted in Biotech, Deals, Guest Blog | Also tagged , , , , , , , , , | Leave a comment

Using Social Networks to Increase Sales

By Ben Comer | Published: May 8, 2012
Social networks existed long before Mark Zuckerberg came along. What hasn’t existed until recently are the tools, metrics and case studies necessary to understand how physicians influence each other within professional networks, and how these relationships can be used to change prescribing behavior.
Posted in Advertising, Marketing, Sales, Strategy, Technology, leadership, social media | Also tagged , , , , , , , , , | Leave a comment

Genentech Runs Voluntary Corrective Ads for Boniva

By Ben Comer | Published: January 18, 2012
Even though Roche-owned Genentech wasn’t required to run costly corrective advertisements following an FDA Untitled Letter on Boniva last January, the company has done so anyway.
Posted in Advertising, Corporate Responsibility, FDA, Legal, Marketing, Regulatory, compliance, leadership | Also tagged , , | Leave a comment

Deals Don't Need Science To Be A Success

By Guest Blogger | Published: September 21, 2011
Deals don’t need science to be a success By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will best be [...]
Posted in Global, Guest Blog, Strategy | Also tagged , , , | 2 Comments